3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
35
Terminated
6
Active not recruiting
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
55
Gastrointestinal
10
CNS
9
Tumor-Agnostic
3
Breast
2
Sarcoma
1
Other solid neoplasm
1
Other neoplasm
1
Head & Neck
1
Conditions
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
108
Radiotherapy
45
Docetaxel
44
Radiotherapy, Intensity-Modulated
36
Gemcitabine
31
Fluorouracil
30
camrelizumab
24
toripalimab
21
Drug Therapy
21
Cetuximab
20
apatinib
19
Paclitaxel
16
Carboplatin
16
pembrolizumab
14
Chemoradiotherapy
14
Capecitabine
13
Blood Specimen Collection
13
sintilimab
12
nimotuzumab
12
Surveys and Questionnaires
10
Surgical Procedures, Operative
10
Endostatins
10
Cyclophosphamide
9
nedaplatin
8
endostar protein
8
durvalumab
8
Nivolumab
8
Neoadjuvant Therapy
8
Induction Chemotherapy
8
fludarabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Erlotinib Hydrochloride
×
Head & Neck
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled